Clinical Trial Update: Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study evaluating PRAME TCR-engineered NK cells for recurrent or refractory melanoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PRAME TCR Engineered NK Cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 1, Recurrent Melanoma | Phase 1 | Status: RECRUITING